Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,527 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: biospecimen Collection Clear all

Conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions: Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Siltuximab; Biological · Procedure · Other
Lead sponsor: Yuanquan Yang; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: Blood test, Questionnaire; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Plasma Cell Leukemia
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 11
States / cities: La Jolla, California • New Haven, Connecticut • North Haven, Connecticut + 8 more

Conditions: Breast Neoplasms
Interventions: Blood draw; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: St Louis, Missouri • Charleston, South Carolina

Conditions: Rectal Cancer, Non-Small Cell Lung Cancer
Interventions: FEED-FF, Standard of Care (SUC); Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: ACH-0145228, Midazolam, Digoxin, Itraconazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Lung Cancer
Interventions: blood draw; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pancreatic Neoplasms
Interventions: blood and bile; Other
Lead sponsor: AdventHealth; Other
Eligibility: 19 Years to 95 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Precancerous Condition, Prostate Cancer
Interventions: immunoenzyme technique, laboratory biomarker analysis; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 45 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Cleveland, Ohio

Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 145
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more

Conditions: Mantle Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib, Positron Emission Tomography and Computed Tomography Scan, Rituximab; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more

Conditions: Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Lymphoma, Extranodal Marginal Zone Lymphoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Nemtabrutinib, Positron Emission Tomography, Rituximab; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Obesity, Non-Alcoholic Fatty Liver Disease
Interventions: Blood Draw, Stool collection, BodPod Measurement, Liver Ultrasound; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 5 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pregnancy Following IVF With PGS/PGD
Interventions: Blood draw; Procedure
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Triple Negative Breast Cancer
Interventions: Needle core biopsy; Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions: Biospecimen Collection, Cabozantinib, Computed Tomography, Everolimus, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Sunitinib; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
Interventions: Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection; Drug · Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sickle Cell Disease
Interventions: Blood draw, Nasopharyngeal wash; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Pancreas Cancer
Interventions: Muscle Tissue Biopsy Sample; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Magnetic Resonance Imaging, Obinutuzumab, Venetoclax; Procedure · Other · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Duarte, California • Irvine, California • Long Beach, California + 4 more

Conditions: Breast Cancer
Interventions: ptDNA, Tissue sample; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atrial Fibrillation, COVID-19, Cancer, Thrombosis
Interventions: [64Cu]FBP8, PET/MR, Blood Collection, Electrocardiogram; Drug · Device · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer, Colorectal Adenoma
Interventions: LifeKit Prevent Colorectal Neoplasia Test, FIT Test; Diagnostic Test
Lead sponsor: Metabiomics Corp; Industry
Eligibility: 40 Years and older
Enrollment: 12,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Carlsbad, California

Search by objective public record fields.

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

A Drug Interaction Study of ACH-0145228

Mechanisms of Immunosurveillance for Lung Cancer

Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)

Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

Evaluation of Intestinal Microbiome in Obese Kids

Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing

Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease

The Role of Muscle Cachexia in Pancreatic Cancer

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

Positron Emission Tomography (PET) Imaging of Thrombosis

Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for CRC Screening